MedPage Today Poll Results Not So Sweet For Diabetes Drug
A majority of healthcare professionals will not prescribe rosiglitazone for their patients with type 2 diabetes.
|
The 'female advantage' in kidney disease does not extend to diabetic women
Sex hormones play a significant role in the development of diabetic kidney disease.
|
MacroGenics Begins Phase 2/3 Study In Type 1 Diabetes Mellitus
MacroGenics's Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes.
|
A Mechanism For Development Of Obesity And Metabolic Syndrome, Forerunners Of Type 2 Diabetes
Roskamp Institute released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes.
|
Awareness Of Advanced Glycation Endproducts In Diabetes Care Is Growing
Diabetes care providers found endocrinologists were universally aware of clinical tests that measure advanced glycation endproducts, a biomarker known to be elevated in people with diabetes.
|
First Prefilled Disposable Insulin Pen For Lantus
Lantus SoloSTAR, a new, disposable insulin pen for people with diabetes is now available.
|
Improving Heart Health In Kids With Type 1 Diabetes
It's never too early to focus on how to maintain good cardiovascular health, especially for people with type 1 diabetes.
|
Americans With Disabilities' Protects Individuals With Diabetes From Discrimination
American Diabetes Association strongly supports the legislation to ensure employees with diabetes and other diseases are given equal opportunity to work.
|
Diabetes Cuts Lifespan, But Exercise Increases It
People with Type 2 diabetes get heart disease about eight years earlier than people with different risk factors.
|
While Most Diabetes Drugs Provide Similar Glucose Control, Some Offer Important Advantages
Most oral medications prescribed for type 2 diabetes are similarly effective for reducing blood glucose.
|
Reducing insulin signaling in the brain can prolong lifespan
Study explains the physiologic benefits of diet and exercise on diabetes and beyond.
|
New Review Adds More Reasons To Avoid Diabetes Drug Avandia
Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes.
|
Older, Less-Costly Diabetes Drugs As Effective As Newer Treatments
Older, less-expensive diabetes drugs are equally as effective and safe as newer, costlier drugs.
|
Gene discovered for type 1 diabetes in children
Pediatrics researchers at The Children's Hospital of Philadelphia and McGill University in Montreal have identified a gene variant that raises a child's risk for type 1 diabetes, formerly called juvenile diabetes.
|
Employers Pay Cash Bonuses To Doctors Providing Optimal Diabetes Care
Thirty-nine clinic sites from 15 medical groups in Minnesota, North Dakota and Western Wisconsin have earned recognition for meeting diabetes treatment goals.
|
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism Of Action For Ranexa
Mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes is discovered.
|
MedApps D-PAL Remote Patient Monitoring System For Diabetes
MedApps announces granting of regulatory clearance for over-the-counter use of the MedApps D-PAL Remote Patient Monitoring System for Diabetes by FDA.
|
Inhaled Insulin For Type 2 Diabetes Shows Mixed Results
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes.
|
Chicago Mayor Daley Recognizes UN Resolution On Diabetes
American Diabetes Association expressed its appreciation to Chicago Mayor Richard M. Daley for becoming the first U.S. mayor to formally recognize the UN Resolution on Diabetes.
|
Weight Loss Up, Medication Down - Diabetics Lose Weight On A Plate
Using a portion control plate helps diabetics both lose weight and decrease their reliance on medication.
|
A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing
New study further demonstrated the safety and efficacy of insulin Levemir (insulin detemir [rDNA origin] injection).
|
DPP-4 Inhibitor Demonstrated Efficacy In Reducing Glucose Levels In Early Phase Study
Alogliptin demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
|
Diabetes Patients Make Significant Gains In Disease Control
Over the last six years, Americans being treated for diabetes improved control of their disease by a significant 44.4 percent.
|
SYMLIN Used In Conjunction With Basal Insulin In Patients With Type 2 Diabetes
SYMLIN injection used in conjunction with basal insulin improved glucose control and reduced weight without increased hypoglycemia in patients with type 2 diabetes inadequately controlled with insulin glargine and oral agents.
|
Short-Term Interruptions In CSII Therapy Result In Blood Glucose Elevations
Short-term interruptions of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes can result in significant elevations in blood glucose levels.
|
Insulin Lantus Lowered Free Fatty Acid Levels Equal To Or Better Than Thiazolidinediones
When added to metformin and/or a sulfonylurea, the once-a-day, long-acting insulin Lantus, significantly reduced free fatty acid levels in patients with type 2 diabetes compared to pioglitazone and had comparable effects to rosiglitazone.
|
BYETTA For Treatment Of Reductions In Cardiovascular Risk Factors In People With Type 2 Diabetes
BYETTA (exenatide) injection sustained improvements in blood sugar levels and progressive weight loss through three and a half years of therapy.
|
Prevalence Of Diabetes Rose 5% Annually Since 1990
Study shows that the prevalence of diabetes rose 5% annually since 1990, and trends in incidence were consistent with the prevalence data.
|
Contrave Has Positive Effect On Visceral Fat, Insulin Resistance
Data from a sub-study of its Phase IIb multi-center clinical trial of Contrave demonstrated robust improvements in both visceral fat and insulin resistance.
|
Rate Of Increase In Diabetes Prevalence Reduced In Raleigh
An 8-year partnership among Centers for Disease Control and Prevention, North Carolina Department of Health and Human Services, Wake County Human Services resulted in a significant change in behavior related to diabetes prevention and care.
|
National Reference Laboratories Now Offer New GlycoMark Diabetes Blood Test
GlycoMark diabetes blood test is now available at major clinical reference laboratories nationwide.
|
New GlycoMark Blood Test To Detect Underlying Treatment Effects
Research underscored the utility of the GlycoMark 1,5-anhydroglucitol (1,5-AG) blood test to detect underlying treatment effects in patients with diabetes.
|
Liraglutide Provides Better Glucose Control Than Insulin Glargine In Phase 3 Study
Novo Nordisk announced clinical results from the first of five phase 3 studies with liraglutide -- the once-daily human GLP-1 analog.
|
Diabetes Drug Supported By Mexican Diabetes Federation
Mexican Diabetes Federation has given Biotech's "Sucanon" diabetes drug its support in an overview of diabetic drugs published in the May-June 2007 issue of Diabetes Hoy.
|
About $80 Billion Go To Provide Care For People With Diabetes
One out of every eight federal health care dollars is spent treating people with diabetes.
|
Women with diabetes left behind in drop in death rates
Death rates for men with diabetes fell steeply, but rates for women with diabetes did not change.
|
ARKRAY Launches Assure 4 Blood Glucose Monitoring System
ARKRAY USA has started to sell its Assure 4 Blood Glucose Monitoring System to the Long Term Care (LTC) market.
|
Nique, Newt Team Up To Fight Diabetes
NBA Hall-of-Famer Dominique Wilkins and former U.S. House Speaker Newt Gingrich will hold a press conference on June 11, to announce a joint effort to fight diabetes in Georgia and beyond.
|
Penn Researchers Find Potential New Target For Type 2 Diabetes
Researchers have discovered a potential new target for treating type 2 diabetes.
|
FDA Approves Continuous 7-Day Glucose Monitoring System
U.S. Food and Drug Administration approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
|
